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Abstract
Our lab has previously showed that carnosol, a naturally occurring polyphenol,
exhibits anti-cancer activity by promoting cell cycle arrest at G2 phase, induces
reactive oxygen species (ROS) dependent apoptosis and beclin-1 independent
autophagy in triple negative breast cancer (TNBC) cell line (MDA-MB-231). Here,
we extended our study by investigating the potential effect of carnosol on migration,
invasion and tumor growth of these cells. Our findings demonstrated that carnosol, at
non-cytotoxic concentrations, exerted a potent anti-metastatic and anti-tumor growth
activity against the highly invasive TNBC cell line, MBA-MB-231. Carnosol
inhibited the migration and invasion of MDA-MB-231 cells. Moreover, carnosol
suppressed the expression and activity of MMP-2 and MMP-9. Remarkably, our
investigation revealed that TNF-α and STAT3 proteins that are involved in invasion
and metastasis signaling were inhibited in MDA-MB-231 cells in response to
carnosol. Furthermore, we demonstrated that carnosol significantly inhibited tumor
growth and metastasis in vivo. In conclusion, our findings identify carnosol as a
promising chemopreventive and chemotherapeutic candidate that modulate breast
cancer growth and metastasis. Hence, carnosol deserves further study and
exploration to identify its downstream mechanism(s) of action.

Keywords: TNBC, tumor anti-migration, tumor anti-invasion and tumor antimetastasis.
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)Title and Abstract (in Arabic

ﺗﺄﺛﯿﺮ ﻣﻀﺎدات اﻻﻧﺘﺸﺎر و ﻣﻀﺎدات اﻟﻨﻤﻮ ﻓﻲ اﻟﻜﺎرﻧﻮﺳﻮل ﻋﻠﻰ ﺳﺮطﺎن اﻟﺜﺪي
اﻟﻤﻠﺨﺺ

ﺗﻮﺻﻞ ﻣﺨﺘﺒﺮﻧﺎ ﻣﺆﺧﺮاً أن ﻣﺮﻛﺐ اﻟﻜﺎرﻧﻮﺳﻮل ) (carnosolوھﻮ ﻣﺮﻛﺐ طﺒﯿﻌﻲ
ﯾﺤﺘﻮي ﻋﻠﻰ ﻣﻀﺎدات ﻟﻠﺴﺮطﻨﺔ ﻣﻦ ﺧﻼل إﯾﻘﺎف دورة اﻟﺨﻠﯿﺔ ﻋﻠﻰ ﻣﺮﺣﻠﺔ ﻣﻌﯿﻨﺔ واﻧﺘﺤﺎر اﻟﺨﻠﯿﺔ
ﻣﻦ ﺧﻼل ﺗﺤﻔﯿﺰ ﺻﻨﻊ اﻟﻤﺸﺘﻘﺎت اﻟﺘﻔﺎﻋﻠﯿﺔ ﻟﻸﻛﺴﺠﯿﻦ واﻻﺗﮭﺎم اﻟﺬاﺗﻲ اﻋﺘﻤﺎداً ﻋﻠﻰ ﺑﯿﻜﻠﯿﻦ١
) (beclin-1ﻓﻲ ﺳﺮطﺎن اﻟﺜﺪي ﺛﻼﺛﻲ اﻟﺴﻠﺒﯿﺔ MDA-) triple-negative breast cancer
 .(MB-231ﺣﺎﻟﯿﺎً ،ﻓﻲ ھﺬه اﻷطﺮوﺣﺔ ﻣﺪدﻧﺎ دراﺳﺘﻨﺎ ﻟﻠﺘﺤﻘُﻖ ﻣﻦ ﻣﻀﺎدات اﻟﺴﺮطﻨﺔ ﻓﻲ
اﻟﻜﺎرﻧﻮﺳﻮل ﻋﻠﻰ ھﺠﺮة واﺟﺘﯿﺎح وﻧﻤﻮ اﻟﺜﺪي اﻟﺴﺮطﺎﻧﯿﺔ .وﺗﻮﺻﻠﻨﺎ ﻣﺆﺧﺮاً ﺑﺄن اﻟﻜﺎرﻧﻮﺳﻮل ﻋﻠﻰ
ﺗﺮاﻛﯿﺰ ﻏﯿﺮ ﺳﺎﻣﺔ ﻗﺎدر ﻋﻠﻰ ﻣﻨﻊ اﻧﺘﺸﺎر وﻧﻤﻮ ھﺬه اﻟﺨﻼﯾﺎ اﻟﻌﺪواﻧﯿﺔ وھﻲ ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﺜﺪي
ﺛﻼﺛﻲ اﻟﺴﻠﺒﯿﺔ  .triple-negative breast cancerﻓﻲ اﻟﻮاﻗﻊ ،ﻓﻘﺪ ﻗﺮرﻧﺎ أن اﻟﻜﺮﻧﻮﺳﻮل ﻗﺎدر
ﻋﻠﻰ ﻣﻨﻊ ھﺠﺮة وﻏﺰو ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﺜﺪي ) .(MDA-MB-231وإﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ وﺟﺪﻧﺎ أن
اﻟﻜﺎرﻧﻮﺳﻮل ﻗﺎدر ﻋﻠﻰ ﺗﺜﺒﯿﻂ ﺗﻌﺒﯿﺮ وﻧﺸﺎط ھﺬه اﻟﺒﺮوﺗﯿﻨﺎت ) .(MMP-2 and MM-9وﻟﻔﺖ
ﻧﻈﺮﻧﺎ أﯾﻀﺎ ً ﻗﺪرة ﺗﺜﺒﯿﻂ اﻟﻜﺎرﻧﻮﺳﻮل ﻋﻠﻰ ﻣﻨﻊ ھﺬه اﻟﺒﺮوﺗﯿﻨﺎت ) (TNF-α and STAT3اﻟﺘﻲ
ﺗﺘﻀﻤﻦ ﻓﻲ ﻣﺴﺎر ھﺠﺮة واﺟﺘﯿﺎح ھﺬه اﻟﺨﻼﯾﺎ .وﻋﻼوة ﻋﻠﻰ ذﻟﻚ ،أﺛﺒﺘﻨﺎ أھﻤﯿﺔ اﻟﻜﺎرﻧﻮﺳﻮل ﻋﻠﻰ
ﻣﻨﻊ ﻧﻤﻮ واﻧﺘﺸﺎر اﻟﺴﺮطﺎن ﻋﻠﻰ اﻟﻜﺎﺋﻦ اﻟﺤﻲ ) .(in vivoوﻓﻲ اﻟﺨﺘﺎم ،اﻟﻨﺘﺎﺋﺞ اﻟﺘﻲ ﺗﻮﺻﻠﻨﺎ إﻟﯿﮭﺎ
اظﮭﺮت اﻟﻜﺎرﻧﻮﺳﻮل ﻋﻠﻰ اﻧﮫ ﻣﻌﺎﻟﺞ ﻛﯿﻤﯿﺎﺋﻲ وواﻗﻲ ) chemopreventive and
 (chemotherapeuticواﻋﺪ ﺑﺤﯿﺚ اﻧﮫ ﻗﺎدر ﻋﻠﻰ اﻟﺘﻼﻋﺐ ﺑﮭﺠﺮة وﻧﻤﻮ ﺳﺮطﺎن اﻟﺜﺪي.
وﺑﺎﻟﺘﺎﻟﻲ  ،ﻛﺎرﻧﻮﺳﻮل ﯾﺴﺘﺤﻖ اﻟﻤﺰﯾﺪ ﻣﻦ اﻟﺪراﺳﺔ واﻻﺳﺘﻜﺸﺎف ﻟﺘﺤﺪﯾﺪ آﻟﯿﺔ اﻟﻌﻤﻞ.
ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :ﺳﺮطﺎن اﻟﺜﺪي ﺛﻼﺛﻲ اﻟﺴﻠﺒﯿﺔ ،ﻣﻀﺎد اﻻﻧﺘﺸﺎر ،ﻣﻀﺎد اﺟﺘﯿﺎح ،ﻣﻀﺎد
ﻧﻤﻮ اﻟﺴﺮطﺎن.
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Chapter 1: Introduction
1.1 Cancer
1.1.1 Brief history of cancer
Cancer has been known to mankind since ancient times. Cancer initiates
when cells in a certain part of the body start to grow out of control. The study of
cancer is termed oncology. One of the first evidence of the existence of cancer was
discovered in fossilized bone tumors in human mummies in ancient Egypt. As it was
referenced in ancient manuscripts, bony skull damage was seen in the head and neck
also. Although the term cancer was not used, the oldest explanation of cancer was
found in a book called “Edwin Smith Papyrus” which dates back to about 3000
BC[1]. The word cancer was coined by the Greek physician, Hippocrates who is
considered as the father of medicine (460-370 BC). Hippocrates used the Greek
terms, carcinos and carcinoma to describe tumors. In fact, this term is used to
describe a crab movement , which he thought behaved like a tumor[2], [3].
1.1.2 Cancer epidemiology
Cancer is a leading cause of death in both developed and developing
countries. Recently, cancer diseases have become a global health problem. The
burden of cancer incidence is expected to increase worldwide from 14.1 million
cases in 2012 to 21.6 million by 2030. In 2012, 8 million cancer related deaths were
recorded worldwide[4].One of the main reasons for the rising burden of cancer is the
aging of the population. Furthermore, tobacco and alcohol consumption, obesity
alongside other risk factors lead to an increase in cancer occurrence[5], [6].
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1.1.3 Cancer characteristics
Cancer is known as a class of disorders or diseases characterized by
uncontrolled cell growth and/or defects in vital and critical control mechanisms such
as the ability to undergo cell death or growth arrest. Additionally, cancer cells are
characterized by their capability to spread from the primary site, or site of origin, to
adjacent tissue through invasion, or by embedding into distant sites by metastasis.
Moreover, cancer cells acquire autonomous growth signals, escape from growth
inhibitory signals, enable replicative immortality, induce angiogenesis (formation of
new blood vessels)[7], [8], genome instability and tumor-promoting inflammation
which are crucial characteristics of cancer. Additionally, they highlighted two other
merging hallmarks that required further study which are avoiding immune
destruction and reprogramming energy metabolism[9].
1.1.4 Classification of cancer
Cancers are very diverse, requiring different treatments and diagnoses. More
than one hundred different types of cancers have been identified. Cancers can be
classified according to the type of tissue in which they originate. There are five main
groups, which are carcinoma, sarcoma, myeloma, leukemia and lymphoma.
Carcinoma start in epithelial tissues, while sarcoma is found in mesoderm derived
cells (such as bone and muscle) and myeloma originate in the plasma cells of bone
marrow. Moreover, leukemia is a cancer that is found in the bone marrow and
lymphoma develops in the glands or nodes of the lymphatic system[8], [10].
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1.2 Breast cancer
It is noteworthy to mention that breast cancer is one of the major causes of
death among women throughout the world. Breast cancer is a malignant tumor that
originates from breast cells. A malignant tumor is made up of a group of cancer cells
that can invade nearby tissues or metastasize to distant areas of the body. Breast
cancer occur mostly in women, although men can have it, too[11].
Understanding the normal breast structure is necessary in order to understand
the breast cancer disease. Breast tissues are made up mainly of lobules (glands that
produce milk), ducts (tubes that transport the milk from the lobules to the nipple and
it has contracting function) and stroma (connective and fatty tissues surrounding the
lobules and ducts, blood vessels, and lymphatic vessels)[10], [12], [13]. Cancers
initiating from ducts are known as ductal carcinomas; while those starting from
lobules are known as lobular carcinomas[14], [15]. There are a number of factors
correlated with an increased risk of breast cancer such as age, family history,
exposure to radiation41 and lifestyle[16].
1.2.1 Descriptive epidemiology
Breast cancer is a serious disease and by far the most frequently diagnosed
cancer in women on a global scale. In 2012, there were 1.7 million cases and 0.5
million breast cancer deaths. The incidence of breast cancer accounted for 25.2% of
all cancer cases and 15% of all cancer deaths in women in 2012. Moreover, breast
cancer incidence rates in developing countries was 2-fold higher than developed
countries and the death rates were found to be 2 to 5-fold higher in developing
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countries than in developed countries[5]. It is predicted that by 2030, the number of
new cases of cancer in the world will increase to 22.2 million[17], [18].
In the United Arab Emirates (UAE), cancer is considered to be the third
leading cause of death after heart diseases and accidents, where cancers cause 15%
of total deaths. In 2012, 20% of diagnosed cancer cases was breast cancer. Moreover,
breast cancer is considered to be the leading cause of death among other cancers like
lung and colon cancers, where it represents 13.3% of all other cancers[19].
1.2.2 Molecular classification of breast cancers
Breast cancer is considered to be a highly heterogeneous group of cancers
that arrive from different cell origins and each has its own clinical implications.
Breast cancer is classified according to the histopathology, tumor grade, tumor stage,
and protein profile and gene expression[20].
The molecular classification of breast cancer is based on examining the
alterations of gene expression that drive cancer. This is important as it has prognostic
significances beyond the traditional prognostic indexes and can aid in the
determination of the most suitable treatment for the individual. Accordingly, at the
molecular level, breast cancer can be categorized into five subtypes which are
luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)
overexpression, basal-like tumors and normal like tumors[21]–[23]. Normal-like
tumors are poorly classified and they need more studies and their clinical
significance is still undetermined[24].
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1.2.2.1 Luminal tumors
Most breast cancers are luminal-like tumors, representing 64.3% of other
breast cancer subtypes. They are highly identified among hormone receptor-positive
cancers like estrogen (ER) and progesterone (PR) receptors[25]. There are two
subtypes of luminal tumors, i.e., luminal A and luminal B[22]. Luminal A breast
cancer has been defined as ER+/HER2- and has low Ki67 (proliferation marker)[26],
while luminal B as ER+/HER2- and has high Ki67[27]. Luminal B tumors are more
aggressive in comparison with luminal A and have higher histological grade and
poorer diagnosis. The treatment of this subtype of breast tumor is mainly based on
endocrine therapy[28].
1.2.2.2 HER2 over-expression tumors
HER2 is a cell membrane receptor tyrosine kinase and it is usually involved
in the signal transduction pathways leading to cell differentiation and growth[29].
Approximately 15% to 20% of all breast cancers correspond to HER2 overexpression[20]. HER2 is distinguished for its role in the pathogenesis of breast
cancer and as a target for therapy. HER2 over-expression tumors are highly
proliferative and aggressive. They have a high histological grade, poor prognosis,
and are highly sensitive to chemotherapy[30]. Recently, combination of anti-HER2
therapies showed promising results in response rate and tolerance[31], [32].
1.2.2.3 Basal-like tumors
Basal-like breast cancers represents around 10% to 20% of breast carcinomas.
The term basal-like was coined because this kind of tumors expresses genes that are
usually

found

in

normal

breast

myoepithelial

cells[33].

According

to

immunohistochemical markers, there are several proposed types of basal-like tumors
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and one of them is the triple negative breast cancer (TNBC) which is negative to ER,
PR and HER2 receptors[34], [35]. Basal-like breast cancers have different clinical
presentations, diverse response to chemotherapy, distinctive histological features and
various outcomes[34], [36].
1.2.2.3.1 Triple negative tumors
TNBCs represent 60% to 90% of all basal-like cases and is known to lack the
expression of ER, PR and HER2[22]. Triple negative is considered to be highly
aggressive and have high proliferative index compared to other breast cancers[37].
Moreover, it is characterized by distinctive molecular profile and

patterns of

metastasis which usually include brain, lung and bone metastasis[38]. Additionally,
they have poor prognosis and relapse very quickly compared to other breast cancer
subtypes[39]. Also, some of the TNBCs are known to have BRCA1 mutations.
BRCA1 is essential for DNA repair mechanisms and its inactivation accumulates
DNA errors and cause genetic instability which could lead to tumor growth[40].
1.3 Targeted pathways and cellular process in breast cancer
At early stages of tumor progression, cancer cells multiply near the site of
origin where their ancestors first started their uncontrolled proliferation. This results
in a primary tumor where the cancer cells will proliferate and expand within the
organ of origin. These primary tumors correspond to about 10% of cancer deaths.
However, the remaining 90% of deaths were found to have metastasized tumors[41],
[42]. Metastasis action is followed by the formation of new blood vessels in a
process known as angiogenesis[8]. Therefore, better understanding of the molecular
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mechanisms of metastasis and angiogenesis is important to develop new treatments
and prevention strategies against breast cancer.
1.3.1 Metastasis
Metastasis is defined as a cascade of events which are connected through a
series of adhesive interaction and invasive processes, along with responses to
chemotactic stimuli[43], [44]. Metastasis has been characterized as a late stage in
cancer progression. The formation of metastasis cascade is extremely complex where
it is composed of several events which correspond to several biological functions.
The steps involved in metastatic process are: (1) invasion, (2) intravasation, (3)
transport, (4) extravasation and (5) metastatic colonization[8], [45], [46] (Fig. 1).

Figure 1: Schematic diagram showing the different stages of cancer metastasis.
Figure modified from[47].
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Cancer cells can’t be viewed as an isolated mass of tumor, but instead as
tissue that receives and recruits signals from surrounding cells, which is termed
tumor-associated stroma or tumor microenvironment. Tumor microenvironment
affects the interactions of tumor cells and its ability to metastasize. Breast tumor
microenvironment is composed of extracellular matrix and different cell types, such
as fibroblasts, immune cells, endothelial cells and adipocytes[48]. All of these
components play a role in the carcinogenesis of breast cells and their ability to
metastasize.
1.3.1.1 Invasion
Invasive and migratory abilities of cancer cells are considered as key features
of metastatic cascade. In order for cells of primary tumor to invade surrounding
tissue, they must escape from the normal molecular restrictions that link nearby cells
to each other. Thus, these tumors cells need to remodel their cell-matrix and cell-cell
adhesion interactions to gain invasive capabilities[8].
Cell adhesion molecules (CAMs) are families of proteins that mediate
heterotypic (distinct cell types) and homotypic (same cell types) recognition[8].
Cadherin is one of the CAMs and it is a transmembranal glycoprotein that interact
with actin component of the cytoskeleton through catenins[49]. Catenins are
involved in the maintenance of tight intracellular adhesion interactions. Cadherincatenin complexes are also involved in the intracellular signal transduction
cascades[50]. For instance, cadherin is known to sequester catenin, preventing
catenin from the association with other downstream signaling, thus possibly
suppressing oncogenic signals[51]. E-cadherin is a member of the cadherin family
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and its abrogation has been shown to be associated with breast carcinoma and
showed fibroblast-like and invasive phenotypes[52]–[55]. Moreover, breast cancer
was shown to display either down-regulation or complete loss of α-, β- and γcatenins[50], [56]. However, Hazan et al. (2000) found that transfection of α-catenin
gene into metastatic epithelial cells resulted in the restoration of intracellular
adhesion[57]. Moreover, another study showed that the transfection with E-cadherin
cDNA resulted in the re-establishment of epitheloid phenotype and abrogate their
invasiveness.
Tumor cells must also break free from the interaction with the normal
extracellular matrix (ECM) components. The interaction between epithelial cell and
ECM involves integrin receptors. Integrin receptors bind to basement membrane
(BM) and ECM through the recognition and interaction with various components of
ECM, such as collagen, fibronectin or laminin, depending on the subunits that form
the integrin[8], [58]. However, altered expression of integrin is found to be involved
in breast carcinomas and to facilitate its invasion. Throughout de-adhesion to
surrounding ECM, consequently tumor cells will be allowed to escape the primary
tumor.
Invasion of cancer cells into adjacent tissues require the action of several
hydrolytic enzymes or proteases, which are released either by cells around the tumor
or by the tumor cells themselves[59]. Matrix metalloproteinases (MMPs) and serine
proteases are two families of proteolytic enzymes implicated in metastasis. The
MMPs family include several proteases, such as gelatinases, collagenases,
membrane-type MMPs and other proteases[60]. MMPs production is induced via
protein named extracellular matrix metalloprotease inducer (EMMPRIN). These
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MMPs act on degrading the structural components of ECM and BM and cleave other
proteins found outside the cells, such as vascular endothelial growth factor (VEGF)
and fibroblast growth factor (FGF)[61]. Consequently, these proteins (VEGF and
FGF) play a crucial role in metastasis and stimulate angiogenesis. Up-regulation of
MMPs were found to be associated with breast, lung and colon tumors.
One characteristic of invasive tumor is coordinated by a process termed
epithelial-mesenchymal transition (EMT) which comprises the conversion of a sheet
of closely connected epithelial cells into highly mobile mesenchymal cells. This
process is found commonly at early stages of embryogenesis. Its characterized by
low expression of epithelial markers (e.g., E-cadherin) and high expression of
mesenchymal proteins (e.g., N-cadherin) and MMPs. These characteristics were
observed in metastasized tumors[8], [62]. Currently, several therapeutic agents are
under study for their capability to decrease cancer invasiveness based on invasion’s
regulators and their inhibitors[63].
1.3.1.2 Intravasation
Intravasation involves the entry of invasive carcinoma cells into lymphatic or
blood vessels and transport them to distant tissues[64]. This process involves several
steps: (1) cancer cells must adhere to vessel wall, (2) basement membrane
destruction via MMPs, and (3) transendothelial migration where carcinomas cell pass
between the endothelial cells into the bloodstream[8], [65].
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1.3.1.3 Transport
Transport and circulation of carcinoma cells through the bloodstream and
lymphatic vessels is in one direction[8]. Once tumor cells enter the bloodstream, they
are exposed to shear forces and interactions that might lead to their destruction.
Though, cancer cells are capable of resisting such destruction by attaching to the
endothelia cells of blood vessels and thereby protecting themselves from the
immunesystem[66].
1.3.1.4 Extravasation
Extravasation is the escape of tumor cells from lymphatic or blood vessels to
initiate secondary metastatic out-growth, and it can be taken as the reverse of
invasion[59], [67]. This process involves the adherence of tumor cells to endothelial
part of the blood vessel, penetration of endothelial wall, passage through the basal
membrane, and migration into surrounding stroma[8], [10].
1.3.1.5 Metastatic colonization
Metastatic colonization is the formation of a progressively growing tumor at
the secondary tissue. The microenvironment of the new metastatic site differs
completely from the the site of primary tumor. Cancer metastasis is an organselective event, where carcinomas cells will spread to specific and suitable
environment in which they grow and develop[68].
1.3.2 Angiogenesis
Successful tumor metastasis cannot be completed without angiogenesis.
Angiogenesis is the process of forming new blood vessels. This process has an
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essential role in the formation of new vascular network to provide oxygen and
nutrients and to remove waste products from cancer cells[69]. Recently, the
involvement of angiogenesis in tumor progression has been extensively studied.
1.3.2.1 The process of angiogenesis
The regulation of angiogenesis depends on a net balance between antiangiogenic factors and pro-angiogenic factors. Pro-angiogenic factors involve
VEGF, tumor necrosis factor (TNF-α) and other factors that are secreted from tumor
cells or mobilized from the ECM. The first event in angiogenesis is the ‘angiogenic
switch’ which is the switch of non-angiogenic tumor to be angiogenic tumor[8].The
angiogenic switch in tumors involves two main events: (1) up-regulation of proangiogenic factors and/or down-regulation of anti-angiogenic factors; (2) hypoxia
that activates hypoxia inducible factor-1 (HIF-1), resulting in VEGF production[70].
The process of angiogenesis involves (1) the production of cytokines (by
carcinoma and surrounding stromal cells) and proteases (by endothelial cells) to
degrade vascular BM, (2) the migration and proliferation of endothelial cells through
the breached BM towards tumor cells and formation of endothelial tube (3)
recruitment and attachment of mesenchymal cells to the endothelial cell tube and
blood vessels maturation with the formation of vascular basement membrane[64],
[71]. Several ECM proteins and angiogenic factors are involved in angiogenesis.
Upon stimulation of angiogenic factors, proteases such as MMPs get
activated and start degrading vascular BMs leading to the migration of activated
endothelial cells into interstitium. Proteases also fragment some ECM proteins such
as type IV collagen, which leads to the migration of endothelial cells[72].
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Additionally, some of the matrix components, such as fibronectin, fibrin, and others
were found to guide endothelial cells to their targets and provides a supportive
scaffold, and subsequently facilitating the formation of neovessels[73].
1.3.2.2 Factors involved in regulating angiogenesis
1.3.2.2.1 Angiogenic inducers
Several growth factors and endothelial-specific factors (i.e., VEGF) are
involved in the induction of angiogenesis. The role of VEGF in angiogenesis
regulation has been intensely investigated. VEGF is one of the first player in the
initiation process of angiogenesis. VEGF-signaling is vitally involved in
physiological and pathological angiogenesis specifically in tumor growth. The VEGF
gene family comprises of VEGF-A, VEGF-B, VEGF-C, and placental growth factor
(PlGF)[74]. VEGF-A is a key regulator of blood vessel growth, and VEGF-C and
VEGF-D are required in lymphatic angiogenesis regulation[8].
VEGF induces the proliferation and growth of endothelial cells in vitro , and
provokes angiogenic response in vivo[74], [75]. Additionally, it induces the survival
of endothelial cells through activating phosphatidylinositol (PI)-3 kinase-Akt
pathway and producing anti-apoptotic proteins[76], [77]. Moreover, it promotes
vascular permeability, causing inflammation and other pathological conditions[78],
[79]. Also, over expression of VEGF has been studied in various human
malignancies including breast, colon, and lung cancers. An in situ hybridization
study of human breast carcinomas samples showed high VEGF expression,
compared to normal breast cells[80]. Subsequently, VEGF might be a good target for
breast cancer treatment.
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1.4 Breast cancer treatments
Today’s therapies for breast cancer include several approaches consisting
mainly of surgery, radiation therapy, chemotherapy, hormonal therapy and combined
therapy. These approaches can all be used in both the curative and the maintenance
of curation from breast cancer.
1.4.1 Conventional treatments for breast cancer
Once breast cancer gets diagnosed, usually the treatment is started with either
surgical removal of discrete tumor from breast (lumpectomy) or the entire diseased
breast (mastectomy) following adjuvant systemic therapy to decrease the risk of
relapse. Mastectomy is found to be effective therapeutic approach for breast cancers
with BRCA mutations[81]. Also, it is commonly used for invasive breast cancers at
early stages[82]. Lumpectomy is used alone or in combination with radiotherapy, and
it is reported to be more suitable therapy for invasive breast cancer[83].
Radiotherapy is the exposure to a specific ionizing radiation from an external
source which will ultimately damage the cells through direct ionization of DNA,
mediated by (reactive oxygen species) ROS generation via radiation-induced water
hydrolysis and production other toxic radicals. Moreover, Radiotherapy disturbs
cellular homeostasis which will trigger the apoptosis pathway. Radiotherapy has an
important role in the reduction of cancer recurrence and it is applied usually after
surgery[84].
Usually chemotherapy is applied immediately after surgery or before
surgery[85]. Chemotherapy is recommended for all women with invasive breast
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cancer that is greater than 1 centimeter. Neo-adjuvant chemotherapy is used to
reduce the size of a tumor and to prevent the development of micro-metastasis before
the surgery. Adjuvant chemotherapy is used to reduce the risk of relapse [86]. There
are different chemotherapy regimens that are used, each based on specific
characteristic of the tumor type and status. Generally, the main effect of
chemotherapy is believed to kill cells by inducing apoptosis in the malignant cells by
targeting specific cellular mechanisms[87], [88].
Breast cancer develops in epithelial tissues of the breast, which are known to
proliferate under hormonal control. Therefore, breast cancer is often treated with
endocrine modulators when tumor cells retain their hormonal receptors. For instance,
tamoxifen, an ER regulator which binds to ER and blocks estrogen from binding to
it, is usually given to premenopausal women. However, endocrine therapy fails to
cure TNBCs as they lack hormonal receptors[89].
1.4.2 Targeted treatments for triple negative breast cancer
TNBCs do not respond to hormonal therapy and they are highly resistance,
aggressive, metastasize and invasive. At present, many researches are going on to
further characterize the TNBCs and find target therapies for them. Some clinical
studies suggested new agents that are effective on the triple negative tumors.
1.4.2.1 Metastasis inhibitors
While metastasis is the main cause of death in breast cancer patients, antimetastatic therapeutic agents are rarely developed. Interestingly, Esak Lee and his
group reported a novel peptide (called collagen IV peptide SP2012) which inhibits
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the growth and metastasis of breast cancer. SP2012 is found to inhibit breast cancer
growth, metastasis, blocks angiogenesis and lymphangiogenesis. This SP2012
peptide inhibits lymphatic and blood endothelial cell viability, migration, adhesion,
and tube formation by targeting MET (mesenchymal-epithelial transition)
signals[90].
1.4.2.2 Angiogenesis inhibitors
TNBCs are known to be highly aggressive with enhanced angiogenesis and
have been found to have high expression of VEGF. A discussed earlier, VEGF is a
key mediator of angiogenesis, it stimulates endothelial cell proliferation and
regulates vascular permeability in breast cancer[91]. Therefore, targeted therapy
against angiogenesis can be preventive for breast cancers.
One agent involves targeting angiogenic factors such as VEGF is
bevacizumab. Bevacizumab is a humanized recombinant monoclonal antibody which
recognize all known isoforms of VEGF[92]. A study showed that bevacizumab
alone has no effect on breast cancer in terms of tumor growth delay. However, a
combination of bevacizumab with chemotherapy (i.e., docetaxel) showed 47%
reduction in tumor progression[93].
1.4.3 Plant-derived anti-cancer agents
Natural plants have been used as medicine to prevent and to cure several
diseases for thousands of years. Plants have been found to be an excellent source of
bioactive compounds which have beneficial health effects, and very often, these
plants are edible and used in culinary. Certain bioactive compounds from plants have
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been found to have anti-cancer activities, therefore, plants became one of the main
interests for researchers.
1.4.3.1 Phytochemicals
Phytochemicals are natural compounds that are derived from plants.
Thousands of phytochemicals have proved to possess chemo-preventing activities
against cancers without having severe side-effects compared to conventional
treatments[94]. Many cancer therapy researches have aimed to identify and develop
new chemotherapeutic agents that are derived from plants. Different phytochemicals
found in diet were tested and were found to have toxic effects on breast cancer cells
in vitro and prevent breast cancer progression in vivo[95]. Moreover, phytochemicals
have been shown to target breast cancer through inhibiting cellular proliferation,
suppressing inflammatory response, arresting cell cycle, causing apoptosis and
modulating gene expression (such as up-regulation of tumor suppressing genes and
suppressing angiogenic and invasion genes)[96].
Examples of plant-derived agents in preclinical development are paclitaxel
and docetaxel taxanes. These are compounds obtained from yew tree and they
showed anti-tumor activity against metastatic breast cancer and ovarian cancer. They
also induced mitotic arrest and apoptosis[97], [98]. Another example is DNA
topoisomerase I inhibitor β-lapachone obtained from the Lapacho tree. It induces cell
cycle arrest at G1 or S phase and causes apoptotic or necrotic cell death in different
type of human carcinoma cells, including breast, ovaries, colon, lungs and
prostate[99]–[101]. Additionally, apigenin is a flavone compound extracted from
vegetables such as chamomile, celery and other plants. It exerts cytotoxic activities
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against breast cancer and colon cancer cell lines[102]. Apigenin also has a
chemoprevention activities against cancer cells and induces a process of autophagic
cell death[103]. Another plant-derived agent in clinical was derived from a spice
Bleekeria vitensis. Elliptinium was found to have anti-breast cancer activitiy and is
marketed in France nowadays[104].
During the past decades, there has been substantial progress in identifying
how certain phytochemicals are able to interfere with specific events in the process
of carcinogenesis. Epigallocatechin gallate (EGCG) is a chemopreventive and antioxidant polyphenol that is found in green tea. It has been shown that EGCG
suppressed VEGF production via inhibiting the activation of both STAT3 and NF-κB
in human breast cancer cell lines[105], [106]. NF-κB has been reveled to be antiapoptotic and it stimulates tumor proliferation, while STAT3 is found to be
associated with tumor metastasis and angiogenesis[107]. Further investigation, are
needed to understand the anti-carcinogenic actions of phytochemicals.
1.4.3.1.1 Carnosol
Since prehistoric times, mediterranean herbs such as sage and rosemary have
been used for their medicinal properties and culinary purposes. Sage and rosemary
have been known to contain various polyphenolic compounds such as carnosol,
rosmanol, carnosic acid, rosmarinic acid as well as others[108]. Carnosol was first
isolated from sage in 1942 and its chemical structure identified by Brieskorn et al. in
1964[109]. Carnosol is a phenolic diterpene and is synthesized from carnosic
acid[110], [111]. Carnosol was reported to have potent anti-oxidant, antiinflammatory and anti-cancer properties[112].
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The accumulation of ROS and the reduction of anti-oxidants have been
known to promote various biological responses including inflammatory conditions,
neurodegenerative disease, cardiovascular disease, and carcinogenesis of several
tissues[113]. Rosemary extracts were revealed to have radical scavenging activity
which was mainly attributed to carnosol and carnosic acid[114]. Moreover,
deregulated inflammatory signaling lead to excess nitric oxide (NO) production that
occur during inflammation and the multi-step process of carcinogenesis. This
encouraged the search for agents that decrease inflammatory signaling cascades.
Carnosol was reported to reduce nitric oxide production through the inhibition of
NF-kB, p38 and mitogen activated protein kinase (MAPK) in mouse macrophages
which provide possible mechanisms for anti-inflammatory action[115].
In addition, carnosol has been shown to elicit chemopreventive effects by
blocking the activation of carcinogens, inhibiting cell proliferation, inducing
apoptosis selectively in cancer cells, and blocking tumor angiogenesis and
invasion[116]. Carnosol repressed proliferation and stimulated apoptosis in several
human cancer cells. This compound was found to induce cell cycle arrest at G2/M
phase and to decreased mitotic exit of human colon cancer (Caco-2) cells through upregulation of cyclin B expression[117]. Similarly, carnosol induced G2/M phase cell
cycle arrest in human prostate cancer (PC3) cells through down-regulation of several
cyclins (A, D1, and D2), and cyclin-dependent kinases (Cdk), and up-regulation of
Cdk inhibitors (i.e., p21 and p27). Furthermore, carnosol caused apoptosis cell death
in PC3 cells via activation of caspase-8 and -9, stimulation of Bax and inhibition of
B-cell lymphoma-2 (Bcl-2) expression[118]. The anti-proliferative activity of

20

carnosol in human leukemia (HL-60) cells were associated with G1 arrest, caspase-3
activation and induction of apoptosis[119].
Moreover, carnosol exhibits anti-angiogenic and anti-metastatic properties.
This phenolic compound was found to prevent the migration of human umbilical vein
endothelial cells (HUVEC) and human bronchial aortic endothelial cells (BAEC) and
decreased activity of MMP-2[119]. Also, carnosol repressed

the migration of

metastatic mouse melanoma (B16/F10) cells in vitro by inhibiting the expression of
MMP-9[120], [121]. In vivo studies, were survival of rats with acute myeloid
leukemia was improved by administration of carnosol alone or in combination with
vitamin D, which revealed a strong anti-proliferative effect[122], [123]. Additionally,
it was able to decrease tumor multiplicity in a mouse model with colon cancer[124].
1.4.3.1.1.1 Carnosol and breast cancer
Carnosol was investigated for its anti-breast cancer properties. This
compound has been shown to have cytotoxic activity against MCF-7 human breast
cancer cells[125]. Likewise, carnosol was observed to decrease the cellular viability
of T47D[126], AU565[127], and MDA-MB-231 human breast cancer cells[128].
Additionally, the anti-growth activity of carnosol as a single agent or in combination
with other chemotherapeutic drugs or phytochemicals against breast cancer cell line
was evaluated. They found that carnosol reduced cellular viability in human breast
cancer, and suppressed the adhesion of cancer cells to fibronectin. The combination
therapy with other phytochemicals such as curcumin increased the anti-proliferative
activity of carnosol and resulted in a synergistic reduction of viability in MDA-MB-
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231 cells. These results provide additional evidence about the anti-breast cancer role
of carnosol and its potential activity in blocking the growth of tumor cells[129].
Recently, our lab investigated the in vitro and in vivo anti-cancer effects of
carnosol in TNBC and the data were consistent with a model shown in Figure 2[128].
They found that carnosol significantly inhibited cellular viability and colony growth
and induced G2 arrest in the MDA-MB-231. Cell cycle blockade was associated with
up-regulation of p21/WAF1 expression and down-regulation of p27. Furthermore,
carnosol was found to induce beclin1-independent autophagy and apoptosis in MDAMB-231 cells. The coexistence of both events, apoptosis and autophagy, was
confirmed by electron microscopy. Autophagy induction was found to be an early
event, detected within 3 hours post-treatment, which consequently led to apoptosis.
Carnosol treatment also caused an increase in the levels of phosphorylated
extracellular signal-regulated kinase 1 and 2 (pERK1/2) in a dose-dependent manner.
Additionally, they showed that carnosol induced DNA damage, reduced the
mitochondrial potential and prompted the activation of the intrinsic and extrinsic
apoptotic pathways. Moreover, they found that carnosol induced a dose-dependent
production of ROS, and inhibition of ROS by tiron (a ROS scavenger), prevented the
induction of autophagy and apoptosis and attenuated DNA damage. These findings
provide a strong evidence that carnosol may be an alternative therapeutic agent
against the aggressive form of breast cancer and thus deserves more
exploration[130]. Here, therefore, we decided to expand our study by investigating
the potential effect of carnosol on cell migration, invasion and tumor growth of the
TNBC.
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Figure 2: Hypothetical model demonstrating the differential effect of carnosol in
MDA-MB-231 triple negative breast cancer cells[128].
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Chapter 2: Materials and Methods
2.1 Cells culture and reagents
Human breast cancer cells MDA-MB-231 were maintained and cultured in
Dulbecco Minimal Essential Medium (DMEM) (Hyclone, Cramlington, UK). The
media was complemented with 10% fetal bovine serum (FBS) (Hyclone,
Cramlington, UK), 100 U/ml penicillin/streptomycin (Hyclone, Cramlington, UK).
Carnosol was obtained from Sigma Aldrich. TNF-α antibody was obtained from
Abcam. Antibodies to pSTAT3, β-actin, goat anti-mouse IgG-HRP (sc-2005) and
goat anti-rabbit IgG-HRP (sc-2004) were obtained from Santa Cruz Biotechnology,
Inc. LY294002 was purchased from Sigma-Aldrich.
2.2 Wound healing migration assay
In brief, MDA-MB-231 cells were grown in 6-well tissue culture dishes until
they reach confluence stage. A scrape was made over the confluent monolayer with a
sterile plastic pipette tip of 1 mm diameter. Three wounds were made for each
sample or well. Afterwards, the plates were washed twice with 1X PBS and
incubated at 37°C in fresh DMEM supplemented with 10% fetal bovine serum in the
presence of vehicle (Dimethyl Sulfoxide (DMSO)) or indicated concentrations of
carnosol. At the bottom side of each dish, three random places were marked where
the width of the wound was photographed with an inverted microscope at 40X
magnification (Nikon Ti-U, Nikon). Wound closure was determined by measuring
the distance (µm) between the edges of the wound at time 0, 6 and 24 hours, using
the NIS-Elements BR 3.0 software (Nikon). Quantification of the distance migrated
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by the cells was done as follow: D = (Size of the wound at t = 0 h –size of the wound
at t = 6 or 24 hours).
2.3 Matrigel invasion assay
Invasiveness of the MDA-MB-231 cells treated with carnosol was tested
using BD Matrigel Invasion Chamber (8-µm pore size; BD Biosciences, Bedfrord,
MA, USA) according to manufacturer’s instructions. Briefly, MDA-MB-231cells (1
x 105 /well) were placed in 0.5 mL of media containing vehicle (0.2% DMSO) or the
indicated concentration of carnosol were seeded into the upper chambers of the
system; the bottom wells in the system were filled with DMEM complemented with
10% fetal bovine serum as a chemo-attractant and then incubated at 37°C for 24
hours. Non-penetrating cells were removed from the upper surface of the filter with a
cotton swab. Cells that have migrated though the Matrigel were fixed with 4%
formaldehyde, stained with DAPI. Fluorescence from DAPI was detected using a
filter with excitation wavelength of 330–380 nm and barrier filter of 400 nm. DAPIstained nuclei were counted in 10 random fields per well using inverted fluorescence
microscope at 200X magnification (Nikon Ti-U, Nikon). For quantification, the
assay was done in duplicate and repeated three times.
2.4 Measurement of matrix metalloproteinases by ELISA
Cells were seeded in 6-well tissue culture plates in the presence of vehicle
(DMSO) or carnosol for 24 hours. The conditioned medium was collected and the
levels of secreted MMP-9 and MMP-2 were measured using immunoassay kits
(Invitrogen, Camarillo, CA, USA) according to the manufacturer’s protocol.
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Experiments were repeated three times and the average of three means is represented
± SEM.
2.5 Gelatin zymography
Gelatin

zymography

was

performed

according

to

Kleiner

and

Stetlerstevenson’s protocol[131]. Briefly, MDA-MB-231 (2.5 x 106) cells were
incubated in serum-free medium for 24 hours in the presence of vehicle (DMSO) or
carnosol (25 µM and 50 µM). The conditioned medium was collected, concentrated
and 30 µg of total protein was determined in 10% polyacrylamide gels containing
0.1% gelatin. Following electrophoresis, the gels were washed for 1 hour in 2.5%
(v/v) Triton X-100 to remove SDS and then incubated overnight at 37°C in 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM ZnCl2 and 10 mM CaCl2 to allow
proteolysis of the gelatin substrate. Bands corresponding to protein activity were
visualized thruogh negative staining using 0.5% Coomassie brilliant blue R-250
(Bio-Rad, Hercules, CA, USA). Illustrative results from two independent
experiments are shown.
2.6 RNA extraction and RT-PCR
Total RNA from vehicle- or carnosol-treated MDA-MB-231 cells were
prepared using Trizol reagent as described by the manufacturer (Life Technologies,
Inc. Grand Island, NY, USA). RNA expression of MMP-9 was determined by RTPCR. RT-PCR was performed using the Qiagen OneStep RT-PCR kit (Qiagen,
Hilden, Germany) according to manufacturer’s instruction. Equal amounts of RNA
(500 ng) were used as templates in each reaction. The sequences of specific primers
were as follows: MMP-9 sense, 5′-TTGACAGCGACAAGAAGTGG-3′, and
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antisense,

5′-

CCCTCAGTGAAGCGGTACAT-3′;

GGCCTCCAAGGAGTAAGACC-3′,

and

GAPDH
antisense:

sense,

5′5′-

AGGGGTCTACATGGCAACTG-3′. The PCR products were separated by 1.5%
agarose gel and visualized by ethidium bromide staining. Representative results from
two independent experiments are shown.
2.7 Western blotting
Cells (1.8 x 106) were seeded in 100 mm culture dishes and cultured for 24
hours before addition of carnosol at the indicated concentrations. After incubation,
cells were washed twice with ice-cold PBS, scraped, pelleted and lysed in RIPA
buffer (Pierce) supplemented with protease inhibitor cocktail (Roche) and
phosphatase inhibitor (Roche). After incubation for 30 min on ice, cell lysates were
centrifuged at 14,000 rpm for 20 min at 4°C. Protein concentration of lysates was
determined by BCA protein assay kit (Thermo Scientific) and the lysates were
adjusted with lysis buffer. Aliquots of 25 µ g of total cell lysate were resolved onto
8–15% SDS-PAGE along with PageRuler Plus Prestained Protein Ladder (Thermo
Scientific). Proteins were transferred to nitrocellulose membranes (Thermo
Scientific) and blocked for 1 h at room temperature with 5% non-fat dry milk in
TBST (TBS and 0.05% Tween 20). Incubation with specific primary antibodies was
performed in blocking buffer overnight at 4°C. Horseradish peroxidase-conjugated
anti-IgG was used as secondary antibody. Immunoreactive bands were detected by
ECL chemiluminescent substrate (Thermo Scientific). Where needed, membranes
were stripped in Restore western blot stripping buffer (Thermo Scientific) according
to the manufacturer’s instructions.
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2.8 Animal studies
All animal experiments were conducted in accordance with the French
guidelines on the use of animals in scientific investigations with the approval of the
local Ethical committee, (Institut Albert Bonniot, Grenoble, France: licence protocol
N°381029 and B3851610001).
2.9 Chick embryo tumor growth and metastasis assay
The chick embryo tumor growth assay (INOVOTION, Grenoble, France) was
performed as previously described[132], [133]. Briefly, Fertilized White Leghorn
eggs, obtained from the Société Française de Production Agricole (SFPA, St. Brieuc,
France), were incubated at 38°C with 60% relative humidity for 10 days. According
to the French legislation, no ethical approval is needed for scientific
experimentations using oviparous embryos (decree n° 2013–118, February 1, 2013;
art. R-214–88). At stage E10, the chorioallantoic membrane (CAM) was dropped by
drilling a small hole though the eggshell into the air sac and a 1 cm2 window was cut
in the eggshell above the CAM. Cultured MDA-MB-231-GFP were detached by
trypsinization, washed with complete medium and suspended in serum free meduim.
A 50 µL inoculum of 1 x 106 MDA-MB-231-GFP cells was added onto the CAM of
each egg. Eggs were then randomized in 4 groups of 15 eggs (to get sufficient
surviving embryos at the end of the experiments). One day later, tumors began to be
detectable. They were then treated during 8 days, every two days (E11, E13, E15,
E17), by dropping 100 µL of either carnosol (50 or 150 µ g/mL), colchicine (2 µ M)
or vehicle (0.02% DMSO in PBS onto the tumor. At E19 the upper portion of the
CAM was removed, transferred in PBS and the tumors were then carefully cut away
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from normal CAM tissue and weighted. In parallel, a 1 cm2 portion of the lower
CAM was collected to evaluate the number of nodules, containing GFP-expressing
cells. The fluorescent nodules were visualized in situ using whole mounts of tissue
fixed in 4% formaldehyde in PBS and flattened between a hollow glass slide and a
thick coverslip. In order to number the nodule, a thorough and complete visual scan
of the piece of the lower CAM was done using Leica Macrofluo fluorescent
microscope (Leica Microsystems GmbH) equipped with GFP filter. Chick embryos
were sacrificed by decapitation.
2.10 Statistical analysis
All statistical analyses were performed using SPSS version 21. Data were
reported as group mean ± SEM. The data were analyzed via one-way ANOVA.
Significance for all statistical comparisons was set at p < 0.05.
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Chapter 3: Results
3.1 Carnosol attenuates the migration ability of MDA-MB-231 human breast
cancer cells
Cell migration is a crucial step in many physiological events. However,
abnormal regulation of cell migration drives progression of various diseases,
including

cancer

metastasis

and

invasion[134]–[136].

Understanding

the

fundamental mechanisms of breast cancer migration is essential for our
understanding of both the pathology of disease and the effect of drug and its
mechanism of action on breast cancer cells.
Therefore, we investigated the effect of carnosol on the migration ability of
MDA-MB-231 cells through using wound-healing migration assay. For this purpose,
we performed the test with two concentrations of carnosol (25 µM and 50 µM) and
periods of treatment (0, 6 and 24 hrs) that were previously shown to be noncytotoxic[128]. As shown in Figure 3A and 3B, carnosol treatment significantly
inhibited cellular migration in a concentration- and time-dependent manner. Our data
demonstrated that carnosol inhibits the migration potential of MDA-MB-231cells.
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Figure 3: Carnosol inhibits the migration of MDA-MB-231 human breast cancer
cells. (A) Confluent culture of MDA-MB-231 cells were wounded by scratching with
a pipette tip and the cells were incubated in DMEM medium supplemented with 10%
fetal bovine serum without (control) and with indicated concentrations of carnosol.
The wound was measured with an inverted microscope 40X magnification and
photographed. (B) Wound healing assay showing that carnosol inhibited the
migration of MDA-MB-231 breast cancer cells in time- and concentration-dependent
manner. Values represent means ± SEM (n=3) distance (µm) that the cells have
migrated in 6 and 24 hrs. Data are representative of three independent experiments.
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3.2 Carnosol inhibits the invasion potential of MDA-MB-231 cells
Invasion of breast cancer cells into surrounding tissue is an initial step in
tumor metastasis. For that reason, we examined the effect of carnosol on the invasive
potential of MDA-MB-231cells in Matrigel-coated Boyden chamber in the presence
of vehicle (DMSO) or carnosol (25 µM). The number of carnosol-treated cells that
has passed through the Matrigel coated membrane was markedly reduced in
concentration-dependent manner by 40%, as shown in Figure 4A and 4B. This
indicate that carnosol efficiently inhibits the invasiveness capability of MDA-MB231cells.
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Figure 4: Carnosol inhibits the invasive activity of MDA-MB-231 cells. (A) MDAMB-231 cells were incubated for 24 hrs with or without carnosol (25 µM) and
LY294002 (20 µM). Cells that invaded into the matrigel were scored as described in
Materials and Methods. DAPI-stained nuclei of invading cells were photographed at
100X magnification under an inverted microscope (Nikon Ti-U, Nikon). (B)
Quantification of invaded MDA-MB-231 into the matrigel. Values represented in
percent were calculated from three independent experiments and are represented as
mean ±SEM. Statistical analysis was performed using one-way ANOVA (*p< 0.05,
**p< 0.005, ***p< 0.001).
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3.3 Carnosol suppresses the expression and the activity of MMP-2 and MMP-9
in MDA-MB-231 cells
Invasion of cancer cells into adjacent tissue requires the action of several
hydrolytic enzymes or proteases (MMPs), which are released either by cells around
the tumor or by tumor’s cells themselves[59]. MMP-9 and MMP-2, among other
MMPs, are known to have a critical role in breast cancer cells invasion and
metastasis[137]. Accordingly, we decided to examine by gelatin zymography assay,
whether carnosol inhibits breast cancer cells invasion by affecting the activity of
MMP-9 and MMP-2 enzymes. As it is shown in figure 5A, MMP-9 and MMP-2
activity was significantly reduced in concentration-dependent manner by carnosol.
Toward that, we examined the level of secreted MMP-9 in the conditioned
medium of carnosol-treated MDA-MB-231cells. The protein level of MMP-9 (Figure
5B) was found to be significantly reduced in response to carnosol treatment.
Furthermore, RT-PCR analysis revealed that MMP-9 mRNA level was reduced in
MDA-MB-231 cells upon treatment with carnosol (Figure 5C). This demonstrates
that carnosol can inhibit the transcription of MMP-9 gene in these cells. Altogether,
our results showed that carnosol significantly inhibits both, the expression and the
activities of MMP-9 and MMP-2.
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Figure 5: The effect of carnosol on MMP-2 and MMP-9 in MDA-MB-231 cells. (A)
Activities of MMP-2 and MMP-9 in carnosol-treated MDA-MB-231 cells. Cells
were treated with 25 and 50 µM carnosol for 24 hrs and then subjected to gelatin
zymography, as described in Materials and Methods, to analyze the activities of
MMP-2 and MMP-9. (B) Effects of carnosol on the secretion of MMP-9 in the
collected conditioned medium of carnosol-treated MDA-MB-231 cells. The levels of
secreted MMP-9 were determined using immunoassay kits as described in Materials
and Methods. Experiments were repeated three times and the average of three means
is represented ± SEM. Student’s t test was performed to determine the significance
(*p< 0.05 and **p< 0.005). (C) Effects of carnosol on the expression of MMP-9
mRNA. MDA-MB-231 cells were treated with carnosol (25 and 50 µM) for 24 hrs
and then subjected to RT-PCR to analyze the mRNA level of MMP-9. GAPDH was
used as an internal control.
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3.4 Carnosol down-regulates the expression of TNF-α protein in MDA-MB-231
Cells
Several studies reported that tumor necrosis factor-α (TNF-α) has particularly
an important role in tumor migration, invasion and angiogenesis in various cancer
including TNBC[138]. Hence, TNF-α should be considered as a target therapeutic
approach for breast cancer treatment. Because we found that carnosol inhibited cell
migration and invasion of MDA-MB-231, we sought to examine the effect of
carnosol on the expression of TNF-α by measuring the protein level of this cytokine.
Figure 6 shows that carnosol induced a marked reduction of TNF-α protein in MDAMB-231 cells. Therefore, our data suggests that down-regulation of TNF-α could
account, at least partly, for the inhibition of tumor growth and metastasis mediated
by carnosol.
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Figure 6: Effects of carnosol on the expression of TNF-α in MDA-MB-231 cells.
Western blot quantification of TNF-α protein in carnosol-treated MDA-MB-231
cells. MDA-MB-231 cells were treated with vehicle (0.2% DMSO) or indicated
concentrations of carnosol for 24 hrs, and then whole-cell extracts were subjected to
Western blot analysis for TNF-α and β-actin proteins. Each lane was loaded with 25
µg of whole cell extracts. Loading was normalized to the levels of β-actin.
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3.5 Carnosol attenuates STAT3 activation in MDA-MB-231 cells
Signal transducers and activators of transcription 3 (STAT3) gets activated by
phosphorylation by various growth factor and is involved in mammary gland
development[139]. STAT3 is classified as an onco-protein because its constitutive
activation can mediate tumorgenesis in nude mice and oncogenic transformation in
cultured cells[140]. Moreover, STAT3 activation can mediate cellular invasion due
to the regulation of MMP-1 and MMP-2 which mediate cell invasion[141]. It also
found to promote cellular proliferation, resistance to apoptosis, tumor angiogenesis,
and migration of cancer cells[142].
Hence, STAT3 is widely recognized as a potential drug target for cancer
therapy. To investigate whether carnosol affects the activation of STAT3 signaling in
breast cancer cells, we analyzed the level of pSTAT3 in carnosol-treated MDA-MB231 cells. We found that carnosol markedly reduced STAT3 phosphorylation, in
concentration dependent-manner in MDA-MB-231 cells (Figure 7). This result
suggests that the carnosol-mediated effect on cell proliferation, migration and
invasion in breast cancer involves the inhibition of STAT3 signaling in breast cancer
cells. Taken together, our data clearly indicate that carnosol exerts its effects on
breast cancer cell proliferation, migration and invasion at least partly through an
inhibition of one key signaling pathway, namely STAT3, known to regulate several
processes such as tumor growth and metastasis in breast cancer.
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Figure 7: Down-regulation of STAT3 in carnosol-treated MDA-MB-231 cells.
Concentration-dependent decrease of phospho-STAT3 in carnosol-treated MDAMB-231 cells. MDA-MB-231 cells were treated with vehicle (0.2% DMSO) or
indicated concentrations of carnosol for 24 hrs, then whole-cell extracts were
subjected to Western blot analysis for the phosphorylated form of STAT3 and for βactin. Each lane was loaded with 25 µg of whole cell extracts. Loading was
normalized to the levels of β-actin.
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3.6 Carnosol inhibits tumor growth and metastasis in chick embryo tumor
growth and metastasis assay
To further confirm the in vitro anti-breast cancer activities of carnosol, we
decided to investigate its effect on tumor growth in vivo by using the chick embryo
model. MDA-MB-231 cells were grafted on the chorioallantoic membrane (CAM)
and formed tumors were treated every 48 h with vehicle, colchicine (2 µM) or
increased concentrations of carnosol (50 and 100 µM). At E 19, tumors were
recovered from the upper CAM and weighted. As it is shown in Figure 8A and 8B,
carnosol significantly inhibited tumor growth compared with the vehicle treatment.
In fact, concentrations of 50 and 100 µM carnosol led to reduced tumor growth by
43.6% and 33.8% respectively. Similar effect (43.6% inhibition) was obtained with 2
µM colchicine.
We next assessed for the ability of carnosol to inhibit metastasis by counting
the number of nodules in the lower CAM in vehicle, colchicine and carnosol treated
tumors. An average of 6.13 nodules were counted in the lower CAM of vehicletreated chick embryo, while an average of 0.63 and 0.6 nodules only were counted in
50 and 100 µM carnosol-treated embryos (Figure 8C). All together, our data clearly
demonstrates that carnosol could efficiently inhibit breast tumor growth and
metastasis in vivo.
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Figure 8: Anti-tumor growth and anti-metastatic activity of carnosol on breast tumor
in chick embryo chorioallantoic membrane model system. (A) MDA-MB-231 (1 x
106) cells were grafted on the CAM of 10 day (E10) chick embryo. Tumors were
treated every 48 hrs with carnosol as described in Materials and Methods. At E19,
tumors were collected and weighted. (B) Quantification of tumor weight in vehicle
(DMSO), colchicine and indicated concentrations of carnosol-treated chick embryo.
(C) Anti-metastatic effect of carnosol. Quantification of nodules observed in the
lower CAM of chick embryo treated with vehicle (DMSO), colchicine or indicated
concentrations of carnosol. Columns represents mean; bars represent SEM.
significantly different at ***p< 0.0005.
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Chapter 4: Discussion

TNBCs represent a challenge for patients and clinicians because of its poor
prognosis and aggressive behavior, with lack of targeted therapies and high mortality
in comparison to other subtypes of breast cancer. Therefore, identification of new
effective therapeutic compounds to treat TNBCs remain an important clinical
challenge.
Cancer progression toward metastasis involves multistep events in which
malignant cells go into local invasion, intravasation, survival in the circulation,
extravasation, colonization and angiogenesis[143]. Currently, most agents used for
cancer treatment aim at blocking specific molecular mechanisms in tumor
progression, such as, inducing cell death, blocking cell cycle progression or/and
inhibiting tumor invasion and angiogenesis. Interestingly, numerous phytochemicals
derived from edible plants have been reported to have anti-cancer activities[105].
However, little is known about the mechanism of action of most chemopreventive
agents. In the present study we investigated the effect of carnosol, a naturally
occurring compound, against TNBC specifically MDA-MB-231 cell line. Our
findings demonstrate that carnosol, at non-cytotoxic concentrations, exerts a potent
anti-metastatic and anti-tumor growth activities against the highly invasive MBAMB-231 cell line. Indeed, we report that carnosol inhibited the migration and
invasion of MDA-MB-231 cells. Moreover, carnosol suppressed the expression and
activities of MMP-2 and MMP-9. Remarkably, our investigation revealed that TNF-α
and STAT3 pathways were inhibited in MDA-MB-231 cells in response to carnosol,
where both proteins are involved in invasion and metastasis. Furthermore, we
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demonstrated that carnosol significantly inhibited tumor growth and metastasis in
vivo in chick tumor growth assay.
Metastases are formed following the completion of a complex succession of
biological events and the earliest step is migration and invasion through the basement
membrane and the extracellular matrix. Thus, to study this step of metastasis, we
assessed the effect of carnosol on cell-ECM and cell-cell interactions and its effect
on cells migration through in vitro wound or scratch assay. Our results revealed that
carnosol inhibited cell migration in the MDA-MB-231 cell line. This finding may
account partially to the anti-metastatic potential of carnosol on TNBCs. For that
reason, since carnosol exerts its anti-migratory effect on breast cancer cells, we
speculated that it might be a valuable agent that can interfere with cancer cells
adhesion to ECM.
Tumor invasion involves the entry of cancer cells that have resided within a
well-confined primary tumor into nearby stroma and thereafter into adjacent normal
tissue. Invasion is a crucial event in the process of tumor metastasis. It includes the
secretion of substances to degrade the extracellular matrix and the basement
membrane and also the regulation of protein expression involved in the control of
cells motility and migration. MMPs are proteases that are capable of degrading a
range of extracellular matrix proteins allowing cancer cells to migrate and
invade[144], [145]. Up to now, there are at least 28 identified MMPs, and 14 of them
were found to be implicated with breast cancer development and progression[146].
Indeed, the up-regulation of MMPs protein expression were found to be associated
with breast cancer metastatic potential[147]. Moreover, several studies of
pathological mechanisms involved in tumor progression and metastasis showed
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MMPs as prominent molecules involved in modeling tumor microenvironment and
driving cancer progression and metastasis[148], [149]. Here, we clearly showed that
carnosol exerts its anti-invasive effect by down-regulating MMP-2 and MM-9
expression and decreasing their activities. Therefore, through inhibiting these MMPs
we might have impressive therapeutic effect against metastatic and invasive breast
cancer.
Inflammation within breast tumor microenvironment is known to be
associated with increased progression and invasiveness and poor prognosis[150],
[151]. Many inflammatory cytokines are involved in the pathogenesis of breast
cancer and they have gained increasing attention by researchers. TNF-α is considered
as key inflammatory cytokine and plays a critical role in the pathogenesis of
inflammatory responses, autoimmune and malignant diseases[152]. Furthermore,
TNF-α stimulates the expression of adhesion molecules included in the invasion of
metastatic tumor cells[153], [154]. Additionally, TNF-α is also a vital molecule in
stimulation of angiogenesis through promotion of endothelial cell proliferation and
improvement of expression of other pro-angiogenic factors[155]. Further, in vitro
activation of TNF-α induces malignant behavior and invasion in breast cancer
cells[156]. Hui-Hui Li et al. suggested that up-regulation of TNF-α expression in
TNBC’s patients is associated with distant tumor metastasis more than other breast
cancer subtypes[157]. In contrast, the knockdown of TNF-α gene expression was
found to be associated with the inhibition of cell proliferation and induced apoptosis
in TNBC[158]. Likewise, inhibition of tumor xenografts in MDA-MB-231 cells by
docetaxel and ulinastatin was correlated with down-regulation of TNF-α expression
and other cytokines expression[159]. Moreover, El Hasasna et al. found that Rhus
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coriaria suppressed TNF-α production in MDA-MB-231 breast cancer cells[160].
Interestingly, here we showed that carnosol inhibited TNF-α expression in MDAMB-231 cells. Taken together, our finding strongly suggests that one possible
mechanism through which carnosol inhibits invasion and tumor growth involves
inhibition of TNF-α pathway.
STAT3 is a cytoplasmic transcription factor that is responsible for signal
transduction from cell surface receptors to the nucleus. STAT3 activation is tightly
controlled under normal physiological conditions[142], [161]. However, compelling
evidence suggest that STAT3 is a master regulator of several key hallmarks of cancer
cells and is found to be constitutively activated in many cancers including breast
cancer[7], [9], [162], [163]. This transcription factor plays a pivotal role in tumor
growth, cellular proliferation[164], resistance to apoptosis regulators[165], invasion,
migration and angiogenesis[166], [167]. For example, in transgenic mice, mutant
allele of constitutively active STAT3 developed significantly more metastatic and
aggressive tumors than those without[168]. Conversely, Kotha et al. reported that
resveratrol, a naturally occurring polyphenolic compound, repressed tumor growth
and induced apoptosis by inhibiting STAT3 signaling in malignant cells like human
breast cancer (MDA-MB-468 and MDA-MB-231), prostate cancer, human
pancreatic

cancer

containing

activated

STAT3

protein[169].

Moreover,

Methylsulfonylmethane (MSM), an organic sulfur-containing natural compound, has
been shown to suppress breast cancer growth by downregulating STAT3 and
STAT5b pathways[170]. Remarkably, in MDA-MB-231 cells, we showed that
carnosol inhibited STAT3 production in dose-dependent manner. Thus, STAT3 is an
attractive target for anti-breast cancer drug development.
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Metastasis is the most lethal aspect of cancer where it involves complex
events that are linked both temporally and spatially. Since therapeutic failures are
usually due to an inability to stop the invasion and spread of cancer rather than to
failure to treat the primary tumor. Experimental methods for studying the metastatic
properties of tumor cells are essential to design the most favorable therapy and for a
basic understanding of the mechanism(s) of tumor progression. The chick embryo
affords a powerful model to assess tumor metastasis in vivo, in which it provides
accessibility to the chorioallantoic membrane (CAM), a well-vascularized tissue that
surrounds the chick embryo. This model is inexpensive and convenient and it has
other advantages: (1) it is immunodeficient, thus tumors will be able to form after
transplantation onto CAM, (2) invasion and attraction of blood vessels are crucial for
tumor growth and this can be easily observed in CAM as it surrounds the
embryo[171], [172]. Therefore, to extend our previous findings we utilized the chick
embryo CAM metastasis assay to model the metastatic process and the affect of
carnosol in vivo. Human breast cancer cells (MDA-MB-231) were transplanted into
CAM’s chick embryo and treated with carnosol. After 19 days, tumors were
recovered from the upper CAM and weighted and nodules in the lower CAM were
counted. Interestingly, we found that carnosol inhibits tumor growth and metastasis
in vivo. All together, our data demonstrate that carnosol could efficiently inhibit
breast tumor growth and metastasis in vivo.
In summary, our data are consistent with a model shown in Figure 9. We
demonstrated, for the first time, that carnosol exerts a potent anti-invasive, antimetastatic and anti-growth effects against the highly proliferative and invasive
human breast cancer cell line (MDA-MB-231). Carnosol modulate the expression
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and/or the activity of proteins that regulate cellular migration, invasion and
angiogenesis such as MMP-9, MMP-2, TNF-α and STAT3. Moreover, this study
demonstrated that carnosol inhibited tumor growth and metastasis in an in vivo tumor
growth and metastasis assay. Therefore, our current findings provide the first
instance of a potential role of carnosol as promising chemopreventive and therapeutic
agent that inhibits breast cancer growth and metastasis by modulating the expression
and activities of several target proteins and/or pathways. Currently, there is a
growing interest in identifying natural derived compounds that affect several targets
or pathways in breast cancer. Thus carnosol certainly merits a lot of attention and
further study to identify its downstream mechanisms of action.

Figure 9: Hypothetic model demonstrating the differential effect of carnosol in
MDA-MB-231 triple.

47

Chapter 5: Conclusion
Chemoprevention by edible phytochemicals is now believed to be an
inexpensive, acceptable, readily applicable and accessible approach for cancer
control. Various phytochemicals derived from edible plants have been shown to
interfere with different stages of tumorgenesis. Many cellular processes and
mechanisms have been shown to account for the anti-carcinogenic actions of dietary
components, but attention has recently been focused on intracellular signaling
cascades as common molecular targets for various chemopreventive phytochemicals.
Here, our study has focused on carnosol, a natural compound found in our
diets, as a potential anti-breast cancer agent. We demonstrated that carnosol
attenuated breast cancer cell migration, invasion and tumor growth in vivo, at least
partially, through down-regulating the expression of TNF-α and STAT3 which
ultimately led to the inhibition of MMP-2 and MMP-9 expression and activity.
Nowadays, increasing number of natural products are being evaluated in
intervention trials for their potential as anti-cancer agents. Even with the major
advances in our understanding of multi-step tumorgenesis, little is known regarding
the mechanism of action of most chemopreventive candidates. The anti-cancer effect
of most dietary phytochemicals are likely to be the sum of several different
mechanisms. Deregulation or disruption of intracellular signaling pathways
frequently lead to malignant transformation of cells. Therefore, it is important to
identify molecules in the signaling cascade that can be affected by phytochemicals to
permit better assessment of their underlying mechanisms. Therefore, naturally
occurring phytochemicals are indeed worthy of further assessment and development
as anti-metastatic and anti-cancer agents for clinical use.
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